





























UnitedHealthcare Pharmacy - Jan. 1 PDL Report

Fully Insured Customers on the Advantage PDL

The Jan. 1, 2012 Prescription Drug List (PDL) and pharmacy benefit updates represent a small percentage of all prescriptions, with the exception of Lipitor – no medications in the top 50 by utilization – but create significant value for our customers. These decisions are designed to drive the greatest total health care value, while preserving affordable choice for members, with the least amount of disruption. For a complete list of clinical program changes, general list of all impacted medications and member communication materials or for more detailed rationale, please visit EmployerServices.com or contact your UnitedHealthcare representative.

Decisions	Assessment	Effective Date
Down-Tiers		
3 ▶ 2 Carbaglu (enzyme deficiency)	▶ All three of these medications offer sufficient health care value to warrant a lower tier placement. Some of the down-tier decisions will be implemented prior to Jan. 1, 2012 so members can take immediate advantage of the cost savings.	1/1/12 or earlier
3 ▶ 2 Letairis (pulmonary arterial hypertension)		7/22/11
3 ▶ 2 Lysteda (menstrual bleeding)		1/1/12 or earlier
New Tier Placements		
3 Lo Loestrin FE (oral contraceptive)	▶ Lo Loestrin FE was evaluated and will now be covered under the pharmacy benefit on Tier 3 since it offers sufficient value compared to alternatives in its therapeutic class.	9/1/11 or earlier
Up-Tiers		
2 ▶ 3 Azor (high blood pressure)	▶ Azor, as a combination product in a crowded category, no longer warrants a Tier 2 placement. The class continues to expand with new, lower-cost generic options along with Tier 1 and Tier 2 alternatives.	1/1/12
1 ▶ 2 fenofibrate (high cholesterol)	▶ Fenofibrate is an expensive generic and continues to maintain a high-price comparable to Tier 2 branded products , no longer warranting a Tier 1 placement.	1/1/12
2 ▶ 3 Humira (rheumatoid arthritis / Crohn's disease / psoriasis)	▶ Humira, as part of our Specialty Pharmacy Program, is in a high-spend, top trend driving class , which has had little management beyond Notification. ProgressionRx (Step Therapy) Program will also be implemented, see section below. The majority of alternatives remain in Tier 2.	1/1/12
2 ▶ 3 Niaspan (high cholesterol)	▶ Niaspan, extended-release version of niacin, has increased in price and no longer warrants a Tier 2 placement when higher value alternatives to treat high cholesterol are available.	1/1/12
2 ▶ 3 Retin-A Micro pump, tube (acne)	▶ Retin-A Micro pump has increased in price by 17% each year for the last three years and no longer warrants a Tier 2 placement. Its Tier 1 generic equivalent is a better value.	1/1/12
2 ▶ 3 Simcor (high cholesterol)	▶ Simcor, a combination of Niaspan and Tier 1 simvastatin, is priced at a premium and adds unneeded costs to an already crowded class. Lower-cost, better value alternatives are available to treat high cholesterol.	1/1/12
2 ▶ 3 Zovirax cream and ointment (viral infections)	▶ Zovirax cream and ointment no longer warrant a Tier 2 placement as oral products are more accessible and effective at treating viral infections .	1/1/12

Decisions		Assessment	Effective Date
Exclusions ¹			
	Pacnex HP / Pacnex LP (acne)	▶ Pacnex HP / Pacnex LP, excluded at launch, contain the widely available OTC ingredient benzoyl peroxide in a cleansing pad form. All prescription benzoyl peroxide products are excluded from benefit coverage as they are available for \$8-12 OTC.	1/1/12
	Sumaxin TS (acne)	▶ Sumaxin TS, excluded at launch, contains the same active ingredient as multiple Tier 1 generic options yet is priced at a significant premium.	1/1/12
	Veltin (acne)	▶ Veltin, excluded at launch, is a combination of two Tier 1 generics in a gel yet is three times more expensive than the individual components, offering no additional health care value.	1/1/12
	Jalyn (benign prostatic hyperplasia)	▶ Jalyn, excluded at launch, is a combination containing similar active ingredients as two Tier 1 generics yet is over twice the price.	1/1/12
	nitroglycerin spray (generic Nitrolingual - chest pain)	▶ Nitroglycerin spray, excluded at launch, is a generic of Nitrolingual pump spray manufactured by the same company , which will also be excluded from benefit coverage.	1/1/12
	Nitrolingual pump spray (chest pain)	▶ Nitrolingual has taken a 65% price increase over the last two years. As a pump spray, it is 20 times more expensive than Tier 2 Nitrostat tablet. Nitromist pump spray is available in Tier 3.	1/1/12
	Tobradex ST (eye infections)	▶ Tobradex ST, excluded at launch, contains the same active ingredient as Tier 2 generic Tobradex yet is priced at a significant premium and is typically a one-time fill product.	1/1/12
	Amturnide (high blood pressure)	▶ Amturnide, excluded at launch, combines three already available medications including two Tier 1 generics priced under \$8 and offers little value in a crowded class.	1/1/12
	Tekamlo (high blood pressure)	▶ Tekamlo, excluded at launch, is a combination product offering little value in an already crowded class and is at least three times more expensive than its Tier 1 generic alternatives combined. Tier 2 options are also available.	1/1/12
	Tribenzor (high blood pressure)	▶ Tribenzor, excluded at launch, is another triple combination product containing already available Tier 2 and Tier 1 options when many less expensive Tier 1 generic alternatives would suffice.	1/1/12
	Tricor 48mg and 145mg (high cholesterol)	▶ Tricor has doubled in price compared to its Tier 2 generic alternative (fenofibrate), minimizing its economic value. Lipofen and Antara remain as Tier 2 brand options.	1/1/12
	Trilipix (high cholesterol)	▶ Trilipix has doubled in price over Tier 2 generic alternative (fenofibrate), minimizing its economic value. Lipofen and Antara remain as Tier 2 brand options.	1/1/12
	Zuplenz (nausea)	▶ Zuplenz, excluded at launch, contains the same active ingredient as Tier 1 generic Zofran (ondansetron ODT) in an oral disintegrating film yet is over 13 times more expensive.	1/1/12
	Alsuma (migraines)	▶ Alsuma, excluded at launch, contains the same active ingredient as Tier 1 generic Imitrex injection in an auto-injector pen device yet is priced at a significant premium. Its recently launched generic (sumatriptan auto-injection) is manufactured by the same company and will also be excluded.	1/1/12
	Beyaz (oral contraceptive)	▶ Beyaz, excluded at launch, is an oral contraceptive (OC) product, generic Yaz, with the addition of folic acid (available OTC) , offering little additional health care value over Tier 1 OC options including Tier 2 Yaz.	1/1/12
	Safyral (oral contraceptive)	▶ Safyral, excluded at launch, is an oral contraceptive (OC) product, generic Yasmin, with the addition of folic acid (available OTC) , offering little additional health care value over Tier 1 OC options including Tier 2 Yasmin.	1/1/12
	Cocet Plus (pain)	▶ Cocet Plus, excluded at launch, is a combination product that is therapeutically equivalent to Tier 1 generic Tylenol #3 , yet more than twice as expensive.	1/1/12
 	Umecta emulsion, foam, suspension, and PD (psoriasis) Umecta Nail Kit (psoriasis)	▶ Umecta products are priced at a substantial premium, over four times more expensive than Tier 1 generic urea products, and offer other formulations to drive their expensive brand use.	1/1/12
	Uramaxin GT (psoriasis)	▶ Uramaxin GT, excluded at launch, contains the same active ingredient as Tier 1 generic Umecta (urea) yet is over three and half times more expensive.	1/1/12

Decisions		Assessment	Effective Date
Exclusions ¹ continued			
	Silenor (sleep aid)	▶ Silenor, excluded at launch, contains the same active ingredient as Tier 1 generic Sinequan (doxepin HCl) yet is over 15 times more expensive . With multiple generic options available, it offers no additional clinical value.	1/1/12
	omeprazole / sodium bicarbonate capsules (generic Zegerid - ulcers, heartburn, reflux)	▶ Omeprazole / sodium bicarbonate (generic Zegerid), excluded at launch, contains the same active ingredients as OTC Zegerid yet is over 15 times more expensive . Brand Zegerid remains in Tier 3.	1/1/12
	Xerese (viral infections)	▶ Xerese, excluded at launch, is a topical combination medication containing the same active ingredients as Zovirax and OTC hydrocortisone and also has a high rate of one-time use. Oral products are more accessible and effective at treating viral infections.	1/1/12
Exclusions ¹ Multiple Product Packaging			
	<ul style="list-style-type: none"> • Analpram Advanced Kit (dermatitis) • Asmalpred Plus (asthma) • Centany AT (infections) • Ciclodan (fungal infections) • Clindacin PAC (acne) • Clobeta (psoriasis) • Desonil Kit (dermatitis) • Ketocon (fungal infections) • Morgidox (acne) • Pediaderm AF (diaper rash) • Pediaderm TA (dermatitis) • Terbinex (fungal infections) 	▶ These products combine two or more already available medications (often a generic and an OTC), package them together, and market it as a new product, typically priced at a premium to its individual components. This recent industry trend only adds additional costs as these medications offer little to no additional health care value over alternatives. As this trend continues, we will continue to aggressively manage these products by excluding them from benefit coverage and driving down overall class costs. The majority of these have been excluded at launch, resulting in minimal member impact.	1/1/12
	<ul style="list-style-type: none"> • Comfort Pac Tizanadine (muscle relaxant) • Keralyt Scalp Kit (psoriasis) 		1/1/12
Select Designated Pharmacy Program			
	High Blood Pressure: <ul style="list-style-type: none"> • Tekturna • Tekturna HCT 	▶ Select Designated Pharmacy Program targets select Tier 3 medications that have multiple lower-cost Tier 1 and/or Tier 2 alternatives available, and could result in substantial savings: on average, members could save up to \$300 per year. Members are directed to move to mail order or a lower-cost option and stay at retail for network pharmacy coverage; prior to needing to move, they will receive two grace fills at retail.	1/1/12
ProgressionRx (Step Therapy)			
	<ul style="list-style-type: none"> • Multiple Sclerosis: Gilenya • Rheumatoid Arthritis / Crohn's Disease / Psoriasis: Humira 	▶ ProgressionRx requires members to try a lower-cost option (known as Step 1) before progressing to a more expensive option (known as Step 2) for benefit coverage. New Gilenya users will be directed to first try another MS medication (Avonex, Copaxone, Betaseron, or Rebif) while new Humira users will be directed to first try Cimzia, Enbrel, Simponi, or Stelara, based on diagnosis. New rheumatoid arthritis users may be required to try two drugs prior to Humira. Current users will be grandfathered and, therefore, will not be required to try a lower-cost option.	1/1/12
Generic Launch - Lipitor			
	atorvastatin (generic Lipitor - high cholesterol)	▶ Atorvastatin (generic Lipitor) is scheduled to launch on Nov. 30 and anticipated to be priced at a premium to the brand. Lipitor will remain in Tier 2 while the generic is placed in Tier 3. Members will continue to pay the same copayment. Users will be notified in advance of this change and point-of-sale messaging will direct the pharmacist to dispense the brand in place of the generic.	11/30/11 ²

¹ For customers that implemented the Exclude at Launch Program, the green icons indicate which medications were excluded at launch and will have minimal to no member impact. For customers that did not, medications are in Tier 3.

² This change is dependent on the launch of the generic which is anticipated to be November 30, 2011. If there is a delay in the launch date, the decision will be re-evaluated.

Please Note: You may need to add language to your Summary Plan Description (SPD) in order to implement some updates. Ask your UnitedHealthcare representative if you need assistance updating your SPD.

For more information about these pharmacy benefit updates, please visit EmployerServices.com or contact your UnitedHealthcare representative.

Decision Definitions Key

Key	Decision	Definition
2 ▶ 1	Down-tiers	Down-tiers refer to medications that move to a lower tier, which can occur at any time throughout the year to provide members with immediate cost savings.
1 ▶ 2	Up-tiers	Up-tiers refer to medications that move to a higher tier because they offer less health care value (either clinically and/or financially) than similar medications in their therapeutic classes.
2	New Tier Placements	New tier placements occur for medications that have been previously excluded at launch, but now offer sufficient health care value to have a tier placement.
DP	Select Designated Pharmacy	The Select Designated Pharmacy Program is a 2004/2007 Rider capability. Members on the high-cost, maintenance drugs in this program will no longer be able to fill their prescription at retail and obtain network benefits. They will be given three options to save: move to lower cost retail options, move to mail, or both.
✘	Exclusions	We do not make the decision to exclude medications from benefit coverage lightly. A medication is only excluded from benefit coverage when it offers no clinical value over other options in its class and its exclusion can be leveraged to achieve significant savings for our customers and preserve affordable choices for members. Multiple Product Packaging Exclusions are medications that contain two or more already available medications (packaged together), most are available generically or over-the-counter. The majority have been excluded at launch and will have little to no member impact.
✘	Continued Exclusions (previously excluded at launch)	These exclusions will have little to no member impact since the medication has been excluded at launch.
STEP	ProgressionRx (Step Therapy)	ProgressionRx directs members to try a lower-cost medication (known as Step 1) before progressing to a higher-cost alternative (known as Step 2).

This does not apply to PacifiCare business administered by Prescription Solutions, by OptumRx UnitedHealthcare® and the dimensional U logo are registered marks owned by UnitedHealth Group Incorporated. All branded medications are trademarks or registered trademarks of their respective owners. Confidential property of UnitedHealth Group. Do not distribute or reproduce without the express permission of UnitedHealth Group.

M49070-F 8/11 B1492-01 FI Adv © 2011 United HealthCare Services, Inc.